Tiragolumab
- Generic Name
- Tiragolumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1918185-84-8
- Unique Ingredient Identifier
- 6XG22YQM2Z
- Background
Tiragolumab is under investigation in clinical trial NCT04513925 (A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)).
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-04-10
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 210
- Registration Number
- NCT05805501
- Locations
- ๐บ๐ธ
Vanderbilt University Medical Center; Vanderbilt University, Nashville, Tennessee, United States
๐บ๐ธEMORY UNIVERSITY; Bone Marrow & Stem Cell Transplant Center, Atlanta, Georgia, United States
๐บ๐ธSCRI Oncology Partners, Nashville, Tennessee, United States
Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 178
- Registration Number
- NCT05798663
- Locations
- ๐บ๐ธ
University of California San Diego Moores Cancer Center, La Jolla, California, United States
๐บ๐ธWashington University Siteman Cancer Center, Saint Louis, Missouri, United States
๐บ๐ธMissouri Baptist Medical Center, Saint Louis, Missouri, United States
Tiragolumab and Atezolizumab in Patients with Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2023-02-27
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Liza Villaruz, MD
- Target Recruit Count
- 3
- Registration Number
- NCT05746481
- Locations
- ๐บ๐ธ
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Immunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC Patients
- Conditions
- Interventions
- First Posted Date
- 2023-02-24
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT05743504
- Locations
- ๐จ๐ณ
National Taiwan University Hospital, Taipei, Taiwan
Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 15
- Registration Number
- NCT05715281
- Locations
- ๐บ๐ธ
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
๐บ๐ธNational Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States
๐บ๐ธNational Institutes of Health Clinical Center, Bethesda, Maryland, United States
Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).
- First Posted Date
- 2023-01-11
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 29
- Registration Number
- NCT05681039
- Locations
- ๐บ๐ธ
M D Anderson Cancer Center, Houston, Texas, United States
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 210
- Registration Number
- NCT05645692
- Locations
- ๐ฆ๐บ
Lyell McEwin Hospital, Adelaide, South Australia, Australia
๐บ๐ธUniversity of Alabama At Birmingham, Birmingham, Alabama, United States
๐ซ๐ทCentre Eugรจne Marquis, Rennes, France
A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)
- Conditions
- Interventions
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 12
- Registration Number
- NCT05459129
- Locations
- ๐บ๐ธ
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
๐ฆ๐บSir Charles Gairdner Hospital; Medical Oncology, Perth, Western Australia, Australia
๐ซ๐ทInstitut de Cancรฉrologie de Lorraine, Vandoeuvre-Les-Nancy, France
Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT05394337
- Locations
- ๐บ๐ธ
M D Anderson Cancer Center, Houston, Texas, United States
An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 8
- Registration Number
- NCT05315713
- Locations
- ๐ง๐ช
Institut Jules Bordet, Bruxelles, Belgium
๐ง๐ชCHU UCL Namur - Mont-Godinne, Yvoir, Belgium
๐ฉ๐ชUniversitaet Duisburg-Essen, Essen, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.